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Abstract
Background: Sarcopenia is a major public health problem in industrialized nations, placing an increasing burden on public
healthcare systems because the loss of skeletal muscle mass and strength that characterizes this affection increases the
dependence and the risk of injury caused by sudden falls in elderly people. Albeit exercise and caloric restriction improve
sarcopenia-associated decline of the muscular performances, a more suitable and focused pharmacological treatment is still
lacking.
Methodology/Principal Findings: In order to evaluate such a possible treatment, we investigated the effects of EGb 761, a
Ginkgo biloba extract used in chronic age-dependent neurological disorders, on the function of the soleus muscle in aged
rats. EGb 761 induced a gain in muscular mass that was associated with an improvement of the muscular performances as
assessed by biochemical and electrophysiological tests. DNA microarray analysis shows that these modifications are
accompanied by the transcriptional reprogramming of genes related to myogenesis through the TGFb signaling pathway
and to energy production via fatty acids and glucose oxidation. EGb 761 restored a more juvenile gene expression pattern
by regenerating the aged muscle and reversing the age-related metabolic shift from lipids to glucose utilization.
Conclusions/Significance: Thus, EGb 761 may represent a novel treatment for sarcopenia both more manageable and less
cumbersome than exercise and caloric restriction.
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Introduction
Sarcopenia, a term coined by Rosenberg [1], is the major
feature of the age-related decline in neuromuscular performances
and is characterized by the loss of skeletal muscle mass as well as
strength [2]. These morphological and functional modifications
result from intrinsic events, such as changes in the muscle fiber
type composition, mitochondrial dysfunction and oxidative
damage, and from extrinsic factors including reduced physical
activity and excessive and/or unbalanced nutritional intake [3].
Exercise and caloric restriction (CR), known to slow down the
impairment of the aged muscle performances [4], are difficult to
manage while a more specific pharmacological treatment
for sarcopenia that would be more suitable for elderly people is
still lacking.
Muscle wasting and weakness associated with sarcopenia may
benefit from drugs that target neurodegenerative diseases, since
sarcopenia shares several features with different age-related
neuromuscular disorders [5]. In this perspective, one of such
drugs is EGb 761, a Ginkgo biloba extract, which has been shown to
be an effective treatment in chronic age-dependent neurological
disorders such as, for example, Alzheimer’s disease [6,7].
Therefore, we treated with EGb 761 aged sarcopenic rats in
order to evaluate whether this compound, similarly to exercise and
CR, improves age-impaired muscular functions. Biochemical and
electrophysiological analyses show that EGb 761 has a protective
effect on muscular wasting and improves soleus muscle isometric
contractile force. These effects are associated, as shown by DNA
microarray analysis, with the restoration of a more juvenile
transcriptional activity of genes relevant for regeneration and
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7998energy production processes in the soleus of aged rats. This is the
first time, to our knowledge, that EGb 761 has been shown to
benefit the aged muscle in mammals suggesting that it may
represent a novel treatment for sarcopenia.
Results
EGb 761 Affects Total Body and Muscle Weights
At the beginning of the experiment, 22 month-old rats were
randomly separated in two groups and were weighted at regular
intervals. The first group, Aged Control (AC), did not receive any
treatment, while the second group, Aged Treated (AT), received
EGb 761 in the drinking water. After 5 weeks of this regimen, the
mean body weight of the AC group was increased by 2.2% while
the rats in the AT group lost 4% (p=0.02) of their initial body
weight, indicating that EGb 761 counteracts the weight gain
naturally occurring in aged laboratory rats (Table 1).
In order to ascertain whether this effect of EGb 761 was
correlated with differences in muscle anatomic-functional features,
we proceeded to further analyses and focused our study on the
soleus muscle, a slow twitch muscle (type I fiber) with predominant
oxidative metabolism. The animals were euthanized and the soleus
muscles dissected and weighted. The soleus mean weight was
increased by 6.5% in the AT compared to the AC group of rats.
Moreover, the ratio of the soleus weight reported to the total body
weight was increased by 13% (Table 1).
This result suggests that EGb 761 affects body and muscle
weight by increasing the muscular mass and, thus, reversing
toward the juvenile values the age-related decrease of the ratio of
muscle v/s body weight. In order to evaluate whether this
phenomenon was also associated with variations of a biochemical
index of age-related muscle wasting processes, we assessed the
effect of the EGb 761 treatment on the circulating creatine kinase.
EGb 761 Decreases Serum Creatine Kinase
We observed a striking decrease in the serum creatine kinase
(CK) levels in AT rats (3716223 U/L), compared to AC rats
(7376178 U/L). Interestingly, the CK value obtained in the AT
rats was closely similar to the value observed in a group of young (Y)
4 month-old rats (370653 U/L). Since CK serum levels act as a
peripheral marker of muscle damage, these findings further suggest
that EGb 761 has a protective effect against the damages that affect
the aging muscle. In order to ascertain whether this protective effect
was also associated with increased muscular performances, we
compared the contractile force of the soleus muscle under different
conditions in the AC and AT groups of rats.
EGb 761 Enhances the Isometric Contractile Force
We measured the maximal force developed by the soleus muscles
of AC and AT rats, either during a single intermittent isometric
twitch or during tetanic contractions, evoked by direct muscle
stimulation and through nerve stimulation (Fig. 1, a–d). The
isometric twitch and tetanus force developed by individual AT
muscles, evoked by direct muscle stimulation, were compared to
the mean values for the AC muscles, normalized to the weight of
the muscle (Fig. 1, e, f). The mean ratio between AT versus AC
was 2.1 for twitch muscle force evoked by direct stimulation
(Fig. 1e) and 1.46 for tetanic contractions at 40 Hz (Fig. 1f),
indicating an improvement of muscle force. For nerve-evoked
contractions, similar values were obtained with a mean ratio of 2.3
for the single twitch (Fig. 1e) and 1.4 for tetanic contraction at
40 Hz (Fig. 1f).
Furthermore, analyses of the peak force-frequency relation-
ship during direct tetanic stimulation (40–100 Hz) revealed that
AT soleus muscles develop significantly higher peak force at 40
and 60 Hz when compared to AC muscles (Fig. 2a). Also, a
significant change on nerve-evoked tetanus peak force was
detected at 40 Hz in AT muscles when compared to controls
(Fig. 2b). Taken together, these results indicate that isometric
force developed by soleus muscle from EGb 761-treated aged
rats is improved with respect to the same-age controls, with an
enhancement dependent on the stimulation frequency since no
significant improvement was detected at the higher stimulation
frequencies studied.
Thereafter, in order to gain insight on the molecular
mechanisms underlying these anatomical, biochemical and
physiological modifications elicited by EGb 761, we analyzed
the global gene expression in the rat soleus muscle by DNA
microarray analysis. The results already obtained point out to
some precise phenomena based on regeneration or energy
production amelioration for the improvement of muscular
functions elicited by EGb 761. Therefore, the analysis of DNA
microarray experiments investigating molecular events associated
with aging and with EGb 761 treatment on global gene
transcription was focused on genes implicated in these processes
on a limited number of rats for each group.
EGb 761 Treatment Elicits Transcriptional
Reprogramming in the Soleus Muscle of the Aged Rat
The DNA microarray analysis identified a total of 1518
genes, out of 9906, modulated either by aging or EGb 761 or
both. Aging affected the expression of 1015 genes, 2/3 of
them, for a total of 626, were down-regulated, while the
remaining 389 were up-regulated, as assessed by comparing
the old sarcopenic (AC) versus the young group (Y) of rats
(Table S1). EGb 761 affected the expression of 618 genes in
nearly equivalent proportions; 333 genes were up-regulated
and 284 genes were down-regulated when comparing the
treated (AT) versus the AC group of aged rats (Table S2).
Among the genes modulated by EGb 761, a total of 115 were
Table 1. Body and soleus muscle weight.
Aged rats Control (11) Treated (12) Young rats (12)
Body weight at T0 (22 months) 605.64624.66 594.10613.74 Body weight at T0 (3 months) 493.2567.28
Body weight at T0 +5 weeks 619.64628.35 570.00615.66 Body weight at T0 +5 weeks 502.2769.98
Soleus weight 132.7368.92 141.3367.41 Soleus weight 152.3663.53
Soleus/body weight ratio 0.2260.02 0.2560.02 Soleus/body weight ratio 0.3160.00
Values represent the mean6S.E.M. Weights are expressed in g for total body and in mg for the soleus muscle. The ratio represent the muscle weight (mg) divided for the
total body weight (in g) for the different rat groups.
doi:10.1371/journal.pone.0007998.t001
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been loaded into the ArrayExpress database (ArrayExpress
accession: E-MEXP-1937, release date: 2009-06-30).
The microarray data was further investigated using hierarchical
clustering analysis based on the overall similarity of the variations
in the genes expression patterns. Permutation analysis was
conducted on the three different groups of rats altogether. About
2/3 of the genes modulated by EGb 761 or Aging showed more
than 30% of expression variability in each of the 3 groups. These
genes were classified as non exploitable (NE) and were not used for
the clustering analysis (see Methods) (Fig. 3). Using this very
stringent approach, four different clusters (A to D) were identified
by Pearson correlation analysis, corresponding to the different
types of gene expression behavior in response to aging and/or
treatment (Fig. 3). The first cluster assembles genes that are
differentially expressed during aging and, then, reverted toward
the young expression level by EGb 761 (Cluster A, Table S3). The
second cluster contains genes that display an additive effect of
aging and EGb 761 on their expression, that is genes down-
regulated or up-regulated during aging and whose expression was
further decreased or increased, respectively, by EGb 761 (Cluster
Figure 1. Contractility studies. Representative examples of isomet-
ric contractile force in isolated soleus muscle from aged controls (a, c),
and EGb 761-treated rats (b, d). In a and b the recordings were obtained
by direct muscle stimulation and in c and d by nerve stimulation. In
each recording (a to d) are shown evoked twitches (0.2 Hz stimulation)
and tetanic contractions (40 Hz, 600 ms stimulation). The force is
expressed in Newton (N). Histograms represent mean values6S.E.M. of
the force (expressed in N/g) for the single twitch (e) and for tetanic
stimulation (f). Mean ratio values between treated and controls are
indicated in respective boxes with number of values (n) used for
calculations. * Significantly different from controls p,0.05.
doi:10.1371/journal.pone.0007998.g001
Figure 2. Force-frequency relationship. Peak force during isomet-
ric tetanic responses in isolated soleus muscles from aged controls (#)
and EGb 761-treated rats (N) obtained by direct muscle stimulation (A)
and by nerve stimulation (B) at frequencies indicated (abscissa) during
trains of 600 ms duration. An interval of 30 s was used between trains.
Each circle represent the mean6S.E.M. (n=3). * Significant different
from controls p,0.05.
doi:10.1371/journal.pone.0007998.g002
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expression is modified by the treatment but not by aging (cluster
C, Table S5), and genes modulated by aging but not by the
treatment (cluster D, Table S6). Since we were interested in the
effect of EGb 761 on aging, we focused our analysis on the cluster
A and B, while the clusters C and D were not further investigated.
Thus, according to the results obtained by clustering analysis,
EGb 761 modified the expression of 30% (115 out of 378) of the
genes affected by aging. This result stresses the impact of the Ginkgo
biloba extract on aging since these genes represent almost 60% (115
out of 198) of the genes regulated by EGb 761.
Validation of the DNA Microarray Results by qPCR on
Selected Genes
In order to validate the DNA microarray results before further
analysis, we analyzed the m-RNA expression levels of 13 selected
genes having different levels of expression by real-time quantitative
RT-PCR (qPCR) in the soleus muscle, including those used for the
microarray.
The comparison of the pattern of expression in the three
different groups of rats between the DNA microarray and the
qPCR analysis established that all the genes displaying variations
in their expression pattern in the transcriptomic analysis were also
showing concomitant variations by qPCR analysis (Fig. 4).
Moreover, among these genes Acvr1, AdipoQ, Bambi, Col5A, Fasn,
Fst and Gmfg, had a similar pattern of variation by DNA
microarray and qPCR analysis both when comparing the young
with the aged group of rats as well as when comparing the aged
with the aged-treated group of rats. Among the remaining genes,
Cd36, Id1 and Ucp3, displayed a similar pattern when comparing
the young with the aged group of rats and Areg, Id3 and Tgf-b,
when comparing the aged with the aged-treated group of rats
(Fig. 4). Therefore, a majority of 20 out of 26 (77%) of the
comparison made with the 3 groups of rats for these 13 genes were
confirmed by qPCR, validating for further analysis the DNA
microarray data.
The EGb 761 Affects Genes Implicated in Regeneration
and Energy Production Functions
We classified all the genes belonging to clusters A and B
according to their biological functions, using the Ingenuity
pathway analysis software and the gene ontology database.
The most relevant of these functions, according to the number
of genes modified both by aging and EGb 761 treatment, are
Figure 3. Microarray data analysis and clustering. Comparison of gene expression profiles of soleus muscle in young rats (Y), aged control rats
(AC) and aged treated rats (AT). Genes are clustered using Pearson’s correlation. Down-regulated genes are represented in green, up-regulated genes,
in red, number of genes is reported in parentheses.
doi:10.1371/journal.pone.0007998.g003
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well as metabolism (Table 2). Among the most relevant genes,
there are cell division control protein 42 (Cdc42)a n d
transforming growth factor b2( Tgfb2), which are ubiquitous
factors that intervene also in the development and regenera-
tion of the skeletal, nervous and connective tissues. Moreover,
the EGb 761 treatment was also associated with the up-
regulation by 50 to 70% of genes specifically implicated in
skeletal muscle development such as Follistatin (Fst), Follistatin
related protein (Fstl1), BMP and activin membrane-bound
inhibitor (Bambi), a2-macroglobulin (A2m), Activin receptor
type I (Acvr1), embryonic Myosin heavy chain (Myh3)a n d
Ryanodine receptor 3 (Ryr3). Since several of these genes
participates also in the TGFb signaling pathway, which plays a
relevant role in the muscle satellite cell proliferation and
differentiation [8], these results suggest that the EGb 761
modifies gene expression in a manner consistent with the
remodeling of the sarcopenic muscle via the modulation of the
myogenesis (Fig. 5).
The other most relevant effect of EGb 761 is related to the
transcriptional reprogramming of genes implicated in metabolic
processes in mitochondria. Namely, EGb 761 induced the down-
regulation of the transcripts for the Fatty acid synthase (Fasn),
responsible for fatty acid synthesis, the Acetyl-Coenzyme A
acyltransferase2 (Acaa2), involved in cholesterol and lipoprotein
synthesis and fatty acid elongation, the Hexokinase 1 (Hk1) and the
Phosphofructokinase 1 (Pfk1), both implicated in glucose metab-
olism. The treatment induced as well the up-regulation of the
transcripts for the Pyruvate dehydrogenase kinase 4 (Pdk4) and the
Fatty acid translocase (Cd36) involved in lipid metabolism and
transport, respectively, and the Uncoupling proteins 1 and 3 (Ucp1
and Ucp3), relevant for energy production (Table 2).
These findings are consistent with a previous observation that
the EGb 761 modifies the mitochondrial functions in several
tissues [9] and suggest that EGb 761 coordinates the expression of
genes that enhance mitochondrial energy production by increasing
lipid beta oxidation and inhibiting glucose oxidation (Fig. 6).
Discussion
Sarcopenia is a major public health problem in industrialized
nations, placing an increasing burden on public healthcare
systems. The progressive loss of muscle mass associated with
advancing age that is characterized by the slowing of movement
and a gradual decline in muscle strength, increase dependence and
the risk of injury from sudden falls in elderly people. Although
caloric restriction and physical exercise have been shown to be
effective treatments for sarcopenia, their effect is limited to slowing
down the progressive loss of muscle mass and functions and their
implementation is problematic in elderly people. Therefore, drug
treatments appear to be more appropriate for sarcopenia, albeit,
until now, no pharmacological therapy has been reported apart
from the suggestion that leucine-rich dietary components may help
the elderly to preserve muscle mass [10]. However, since the
ageing process manifests itself with similar features in different
tissues, it has been suggested that drugs for age-related
neurodegenerative diseases may also be beneficial for sarcopenia
[5]. In this context, EGb 761(IPSEN), an extract of Ginkgo biloba,
has been shown to extend life span of caenorhabditis elegans [11] and
to enhance learning and longevity in rats [12]. Also, in vivo and in
vitro experiments have demonstrated the efficacy of EGb 761 in
protecting against age-related processes such as increase of
oxidative stress, brain mitochondrial dysfunction [9] and chronic
age-dependent neurological disorders [6,7]. Here, we demonstrate
that EGb 761 improves muscle performances, as assessed by
electrophysiological studies, and, quite remarkably, restores a
‘‘juvenile’’ profile in the soleus muscle of old rats by modulating the
transcriptional expression of genes implicated in development/
regeneration and energy production pathways.
We have focused our study and the DNA microarray analysis
on the soleus since this muscle is, in the rat and humans, almost
homogeneously composed by slow twitch type I fibers. Thus, the
age related changes are easier to analyze as they do not result from
fiber type modifications as, for example, in the gastrocnemius and/or
other mixed fiber type muscles.
Figure 4. Graphic representation of gene expression variations. Comparison between variations of gene expression in the different groups
of rats according either to DNA microarray analysis (blue lines) or to qPCR (red lines). Values of the AC (aged control) group are standardized to 1 for
each gene.
doi:10.1371/journal.pone.0007998.g004
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TGFb and several other genes such as Fst, Fstl1, Bambi and Acvr1
that participate to the modulation of the TGFb signaling pathway
during myogenesis. Tgfb2 contributes, with other factors of the
TGF super-family such as BMP, Activin and Myostatin, to
myogenesis [13] (Fig. 5) and may participate to the regeneration
process that is impaired by aging, resulting in the incomplete
structural and functional recovery after muscle injuries in elderly
people [14]. It is noteworthy that TGF-b2 plays a contextual role
in myogenesis, since it inhibits proliferation and differentiation
but, at the same time, promotes the fusion of the satellite cells
depending on the presence or absence of other factors [15].
Fst, one of the genes up-regulated by EGb 761 and associated to
the TGFb signaling pathway, acts as a positive regulator of the
muscle differentiation [16], since, by binding to myostatin, it
prevents the myostatin-induced inhibition of proliferation and
differentiation [17]. Fst expression increases with age as a
protective mechanism in response to the parallel elevation of
myostatin, albeit this compensatory effect is ineffective in
preventing sarcopenia [18]. Accordingly, our data show an
important increase (3 fold) in the expression of Fst in the aged
rats. However, after EGb 761 the over-expression of this transcript
is further boosted by 2 fold (see progression cluster). Moreover,
according to our results, others transcripts such as Bambi, Fstl1 and
A2m, all inhibitors of BMPs and Activin [19], are also up-regulated
by EGb 761 but not by aging, suggesting that the concomitant
action of all these factors on the TGFb pathway mediates the
regenerative effects of EGb 761.
The transcriptomic analysis highlights another major effect of
EGb 761 upon transcripts, such as Fasn, Acaa2, Cd36, Hk1 and
Pdk4, coding for key mitochondrial enzymes associated to lipid and
glucose metabolism and involved in Krebs cycle, b2-oxidation,
fatty acid transport and oxidative stress (Table 2). During aging the
mitochondria shift from lipids to glucose as substrate for energy
production, which results in increased intramuscular fat accumu-
lation [20,21]. EGb 761 decreased the expression of Fasn, involved
in FA synthesis, and Acaa2, implicated in cholesterol and
lipoprotein synthesis and FA elongation, and increased the
expression of Cd36, a FA transporter present in the sarcolemma,
which promotes FA entry in the muscle cell [22]. Since Fasn
increases blood triglycerides and, with Acaa2, favors the accumu-
lation of intramuscular adipose tissue, the down-regulation of these
genes could instead facilitate mitochondrial lipid oxidation (Fig. 6).
The striking four-fold increase of Ucp3 transcripts observed by
the DNA microarray data analysis further stresses the effect of
EGb 761 in optimizing FA utilization. UCP3 is an uncoupling
protein, preferentially expressed in skeletal muscle, whose over-
expression increases the activity of several key mitochondrial
enzymes associated with FA oxidation, and decreases intramus-
cular triglyceride content [23]. Also, UCP3 lowers mitochondrial
membrane potential, notably through fatty acid anion export from
the matrix, and, consequently, decreases reactive oxygen species
Table 2. List of the genes modulated both during aging and after EGb-treatment classified according to the Gene Ontology
database.
Function
Number of Genes
Regulated (up/down) Symbol
Cell Cycle 23/11 A2M, ACPP, AIF1, AREG, ARID1A, CDC42, CDK4, COL1A1, CREG1, FRK, LGALS3,
MAPK14, MPG, P1K3R1, PAWR, PROS1, PVR, RAE1, ROCK2, SDC2, SST, TGFB2, TNC,
TXNIP, XPC/AKAP12, FASN, ID1, ID3, IGFBP5, MSH2, NOTCH1, PRKCH, PLAC8, THBS1, TOB2
Cell Death 20/16 A2M, BIRC2, CDC42, CDH2, DSP, GCLC, HSPD1, IL18, IL6ST, MLLT3, MPG, P4HB, P4WR,
RTN4, RRAS2, SDC2, SST, TGFB2, TXNIP, UCP1/ADIPO, ANTRK2, CCL11, CCL27, COL18A1,
FASN, FKBP5, ID1,IGFBP5, JAG2, PDE4, PIK3R1, PTPN13, RTN4RL1, THBS1, VTN
Cellular Growth and
Proliferation
43/42 ACPP, AIF1, AREG, ARL6IP5, BAMBI, C1QTNF3, CDC42, CDK4, CDK7, COL1A1, CREG1,
CX3CL1, CXCR7, CYP1A1, DSP, EZR, FST, HSPD1, IL18, IL2RB, IL6ST, LCP1, LGALS3, LITAF,
LOC643751, MAPK14, MLLT3, MT1F, NOP5/NOP58, NR1H3, PAWR, POSTN, RASA1,
RHOBTB2, RTN4RRAD, SDC2, SEPT9, SST, TGFB2, TNC, TXNIP, UCP3, XPC/ADIPOQ, AGER,
AKAP12, AQP4, BCAR3, C6ORF108, CCL11, CCL27, CMA1, COL18A1, DLC1, EGR2, ETV6, FAM107A,
FASN, GLA, GPX3, HK1, ID1, ID3, IFIT3, IGFBP5, IHPK2, ITGB4, LCP1, LDHA, LTBP4, NOTCH1, NTRK2,
PALM, PENK, PER1, PLAC8, PRKCH, PTPN13, PTPN3, RASGRP2, RTN4RL1, SYMPK, THBS1, TIMP4, VTN
Skeletal and Muscular System
Muscle development 8/9 BAMBI, COL5A3, FST, IFRD1, IL6ST, MYH10, MYH3, ROCK2/DLC1, IGFBP5, ITGB4, NOTCH1,
PLAC8, RASGRP2, TAGLN, THBS1, TNNT2
Muscle contraction 4/5 CASQ2, MYBPH, PDEAB, RYR3/ADRB2, CNN1, MYBPC2, TNN12, TNNT2
Muscle Disorders 14/11 AREG, C2, CD36, FCGR3A, HLA-DMA, IL18, IL2RB, IL6ST, LCP1, MAPK14, PDE4B, PRMT3,
RPL32, TAP1/ADRB2, ALAS2, CCL11, CXCL9, EGR2, FKBP5, G0S2, PDE4A, RAMP2, WNT5B, ZFP36
Nervous System
Development and Function
24/23 A2M, ARNTL, ATXN10, CDC42, CDH2, CX3CL1, EIF2B5, FRK, FST, HMGB2, IFRD1, IL6ST,
LOC643751, MAPK14, MYH10, NR1H3, PAFAH1B3, RTN4, RYR3, SST, SV2B, TGFB2,
TIMM8A, TNC/ADRB2, AGER, ALDH1A7, AQP4, CNTN2, CXCL9, EGR2, GPM6A, HEYL, HTR1A, ID1,
ID3, ITGB4, JAG2, NELF, NOTCH1, NTRK2, PDE4A, PER1, RAB3A, RTN4RL1, THBS1, VTN
Connective Tissue
Development and Function
10/6 CDC42, CDH2, CDK4, IFRD1, MAPK14, PVR, ROCK2, TGFB2, TNC, UCP1/ADIPOQ, AKAP12,
GCGR, IGFBP5, NPYIR, TOB2
Lipid Metabolism 11/10 A2M, ABCA1, APOD, CD36, CDC42, CYP1A1, GPR175, MAPK14, NR1H3, PDK4, UCP3/
ACSS2, ADIPOQ, BDH2, CCL11, DGAT2, FASN, GLA, LSR, PLCD4, SMPD3
Carbohydrate Metabolism 14/18 CD36, GCKR, GCLC, GNG2, H6PD, IL6ST, MAPK14, PDK4, RAB5A, SLC2A1, SST, UCP1,
UCP3, UGP2/ADIPOQ, ADRB2, ALG2, DCXR, DGAT2, FASN, FN3K, GCGR, GLA, HK1, IHPK2, NPY1R,
PFKFB1, PFKL, PITPNM1, PLCD4, SYNJ2, THBS1
The up-regulated genes are presented in bold characters and the down-regulated genes are in plain characters.
doi:10.1371/journal.pone.0007998.t002
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increase of UCPs activity correlates with extended lifespan in long-
living avian species [24,25] and in mice [26].
As a corollary to the facilitation of FA oxidation, EGb 761 also
inhibited glucose oxidation in mitochondria by down-regulating
Hk1, associated with glycolysis, and by up-regulating the
glucokinase regulatory protein, which inhibits HK1, and Pdk4,
which inhibits the pyruvate dehydrogenase complex (Fig. 6).
Taken together these modifications contribute to the reprogram-
ming of the ‘‘glucose-fatty acid cycle’’, in which free FA compete
with glucose for mitochondrial oxidation [27], toward an
increased utilization of FA, resulting in the increase of energy
production and the reduction of mitochondrial ROS generation
and of intramuscular fat storage (Fig. 6). Other studies on gene
expression that used caloric restriction (CR) or exercise training for
preventing sarcopenia have reported that CR either stimulated
glycolysis, by the up-regulation of enzymes such glucose-6-
phosphate isomerase, and FA synthesis, by over-expressing Fasn
[28–30], or, in agreement with our findings, induced a
transcriptional switch toward an increase of FA metabolism and
a reduction of lipid biosynthesis in the muscle [31]. Exercise
training as well, similarly to EGb 761, improves mitochondrial FA
uptake and oxidation, by reducing the lipid stores in the muscle
[32,33]. Thus, EGb 761 produces effects comparable to CR or
exercise training and represents a more manageable option for the
prevention and treatment of sarcopenia.
Besides these major effects, EGb 761 elicited also the over-
expression of transcripts that are usually present during regener-
ation processes such as Myh3 [34] and Ryr3. The Ryr3, a minor
form of ryanodine receptor, regulates the resting free Ca
2+
concentration and, thus, may favor a sustained contraction with
increased force in the skeletal muscle [35]. In addition, the up-
regulation of the transcripts for Myh10 and Mybph also contribute
to the increase of the muscle strength.
The two-fold increase of Tenascin C (Tnc) gives another
example of how EGb 761 may modulate transcripts that are
relevant for muscle strength. Tnc, in the adult muscles, is an
extracellular matrix (ECM) molecule that localizes in the tendon
along with other components of the ECM such as the collagen I
and III, playing an important role in the force transmission and
tissue structure maintenance. The collagen constitutes 60–85% of
the tendon dry weight and is predominantly type I (,60%)
arranged in tensile-resistant fibers, types III (#10%), IV (,2%)
[36,37], V, and VI [38]. In particular, the type I collagen, carrying
fibrous tensile strength, allows the transmission of force generated
by skeletal muscle into movement [39]. Interestingly, the collagen
I, V, VI expression is increased between 50% and 100% by EGb
761. Therefore, these components of the ECM may reorganize the
Figure 5. Schematic representation of the interactions between the genes regulated by EGb 761 associated to myogenesis/
regeneration in the soleus muscle of aged rats. Regulated genes are included in frames. 8 indicates up-regulation of gene expression by EGb
761. ˆ indicates down-regulation of gene expression by EGb 761. R=activation. --I=inhibition. Activins and BMPs may be diverted into alternative
pathways through interaction with soluble and membrane-bound binding proteins Activin, myostatin and BMPs signal via type II activin receptor.
The access of these TGF-b2 superfamily members to their type II receptors is blocked by extracellular binding proteins (follistatine, Fstl1 and a2-
macroglubulin) and membrane-bound pseudoreceptors (BAMBI for activin signaling).
doi:10.1371/journal.pone.0007998.g005
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muscle strength and body stability, whose impairment represents
the main cause of falls in elderly people.
Finally, mitochondrial function improvement represents the
main factor for the enhancement of muscular strength after
EGb 761 treatment. Mitochondria play a central role in the
production of cellular energy in the form of ATP, but are also
key regulators of apoptosis, which contributes to the aging
processes underlying sarcopenia. The age-related reduction in
ATP production is responsible of the decrease in contractile
force observed during aging. EGb 761 contributes to a better
ATP production and availability by improving FA transport
and utilization.
In conclusion, EGb 761 may represent a novel therapeutic
intervention, endowed with a rejuvenation effect mediated by
transcriptional reprogramming of a majority of genes impli-
cated in aging, and with several advantages over CR and
exercise to prevent sarcopenia in elderly people. Among these
advantages there is a more easily implementation and
therefore a better compliance with the treatment. Moreover,
the effects of EGb 761 are mediated both by the restoration of
the expression of genes that are pathologically down-regulated
by aging and the boosting of the expression of genes that are
physiologically up-regulated to counteract the effects of the
aging process. This is another advantage over exercise and CR
whose action is limited to slowing down the muscular ageing
progression. It is also noteworthy that this effect may be unique
to Ginkgo biloba extract. Indeed, Ginkgo biloba is one of the oldest
life forms and contains many molecules (like ginkgolides) that
do not exist in other organisms and are extremely difficult to
synthesize. Thus, the natural extract of such a living fossil,
shaped by natural selection during several millions of years,
may contain several unique molecules that are less disruptive
than synthetic products and better suited for fitting with
biological systems [40].
Methods
Animals
All animal procedures were performed under authorizations of
the ‘‘Direction des Services Ve ´te ´rinaires de Paris’’ of the
‘‘Prefecture de Police de Paris’’ and strictly followed the guidelines
for the ethical treatment of the animals set forth by French law
(decree Nu 87-848 dated 11/19/1987 and modified by the decree
Nu 2001-464 dated 5/29/2001). The study was conducted with
male Wistar rats on a group of young, 4-months old, rats (Young
group=Y), and two groups of aged, 23-month old, rats. The aged
rats either received (Aged Treated group=AT) or did not receive
(Aged Control group=AC) EGb 761 treatment.
EGb 761 Treatment of Rats
The Ginkgo Biloba extract (EGb 761), provided by IPSEN
laboratories (France), was administered in the water at a dose of
75 mg/Kg body weight for two months. During the 60 days of the
experiment, the animals were weighed each week and the volume
of drinking solution was measured. The AC and AT groups were
sacrificed at 23 months of age, young rats were sacrificed at 4
months.
Determination of Serum Creatine Kinase
Blood samples were taken from the hearts of anaesthetized rats,
immediately before sacrifice. Activities of serum CK were
determined using a Biomerieux kit (enzyline CK NAC optimized
10).
Measurement of Soleus Contractility
Rats were anesthetized with Isoflurane (AErraneH, Baxter S.A.,
Lessines, Belgium) inhalation before being sacrificed by section of
the carotid arteries.
Soleus muscles with their attached nerves were carefully
removed, mounted in a silicone-lined bath filled with Krebs-
Ringer solution continuously perfused with 95% O2 and 5% CO2
throughout the experiment. The Krebs-Ringer solution was
maintained at 2260.5uC instead of 37uC in order to optimize
the experimental conditions, since at a temperature of 37uC the
risk of nerve conduction failure is greatly increased. One of soleus
tendons was securely anchored onto the silicone-coated bath, the
other tendon was attached to an FT03 isometric force transducer
(Grass Instruments, West Warwick, USA).
Muscle twitches and tetanic contractions were evoked either by
stimulating the motor nerve via a suction microelectrode, with
supramaximal current pulses of 0.15 ms duration, at frequencies
indicated in the text, or by direct electrical stimulation. The resting
tension was adjusted for each preparation investigated with a
mobile micrometer stage (to allow incremental adjustments of
muscle length) in order to obtain maximal contractile responses.
Signals from the isometric transducer were amplified, collected,
and digitized with the aid of a computer equipped with a DT2821
analogue to digital interface board (Data Translation, Marlboro,
USA), as previously reported [41]. Data acquisition and analysis
were performed with a program kindly provided by Dr. John
Figure 6. Schematic representation of the interactions between
the genes regulated by EGb 761 associated with regulation of
energy metabolism in mitochondria in the soleus muscle of
aged rats. Regulated genes are included in frames. 8 indicates up-
regulation of gene expression by EGb 761. ˆ indicates down-regulation
of gene expression byEGb 761.R=activation.----I=inhibition. FA (Free
Fatty Acids) are taken up by the fatty acid transporter protein Cd36
and activated to fatty acyl-coenzyme A (FA-CoA). FA-CoA oxidation
would increase the ratios of acetyl-CoA/CoA and of NADH/NAD+,
which inhibit the pyruvate dehydogenase (PDH) complex by
activating the pyruvate dehydrogenase kinase 4 (Pdk4). Increase
FA oxidation products as citrate should further inhibit phospho-
fructokinase (Pfk) and hexokinase. These changes would slow down
oxidation of glucose and pyruvate and glycogen stock is main-
tained. In the same time, fatty acid synthase (Fasn) and mitochon-
drial 3-oxoacyl-Coenzyme A thiolase (Acaa2) are inhibited resulting
in the lipid synthesis inhibition and a preferential use of these lipids
for ATP synthesis.
doi:10.1371/journal.pone.0007998.g006
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expressed as the mean6SEM. The statistical significance of
differences between controls and test values was assessed with
Student’s t-Test (two-tailed). Differences were considered signifi-
cant if /P/,0.05.
Tissue Processing
For microarrays and qPCR experiments the soleus muscles from
each animal were excised, snap-frozen in liquid nitrogen and
stored at 280uC.
RNA Extraction
Total RNA was isolated from an aliquot of muscle thawed
on ice; and extraction was performed by a silica gel-based
purification method (RNeasy Mini Kit, Qiagen). For qPCR,
total RNA was subjected to DNAse treatment (Qiagen) 30 min
at room temperature. Total RNA yield was measured by the
OD260, and the quality was evaluated on nanochips with the
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto,
CA, USA).
Microarrays and analysis
Gene expression levels were measured by using rat oligonucle-
otide arrays as described previously [42]. The microarrays contain
9906 different genes (CodeLink system, Uniset rat I, GE
Healthcare Europe GmbH, Freiburg, Germany). Each experi-
mental group, Aged Treated (AT), Aged Control (AC) and Young
(Y) rats, was formed by 2 rats (biological replicates) and the total
RNA isolated from the soleus muscle was hybridized in duplicate
(technical replicates). Thus 4 microarrays were utilized for each
group of rats.
After hybridization and washing, the slides were scanned using a
Genepix 4000B scanner (Axon, Union City, USA) and Genepix
software. The scanned image files were analyzed using CodeLink
expression software, version 4.0 (GE Healthcare).
CodeLink software was used to normalize the raw hybridization
signal. The threshold of detection was calculated using the
normalized signal intensity of the 100 negative controls, spots
with lower signal intensities were termed ‘‘absent’’.
ESTs were analyzed by BLAST research on the NCBI
nucleotides databases. The clusters were generated using Pearson
correlation. Statistical comparison and filtering were performed
using Genespring software 7.0 (Agilent).
A first selection of genes was performed by pair-wise
comparisons between AT and AC rats (Egb761 effect) or Y and
AT rats (Aging effect). Each sample from one group was compared
with each sample from the other group. This permutation analysis
comparing 3 different group allows for strengthening the relevance
of the findings when a given differences is found across different
groups. To identify significant changes, the following criteria were
used: 1) p-value less than 0.05; 2) a fold change of 1.3 was used to
define a set of significantly up- and down regulated genes; 3) the
over 1.3 fold change should be reproducible across all compar-
isons. Therefore a given mRNA transcript was considered as
differentially expressed in the comparison of any two samples if the
difference gave a P value of #0.05 in the Welch ANOVA
parametric test, using a multiple test correction (Benjamini and
Hochberg False Discovery Rate). Moreover, to avoid false positive
genes, in particular for genes with small variation between groups,
we removed from the two lists above genes with variability $30%
inside each of the three groups (Y, A and AT), those genes were
classified as non exploitable (NE). Thus, a gene was considered for
the clustering analysis only if it met the above criteria in all
pairwise comparisons and if the detected signal was above the
background for at least one of the compared groups, thereby
carrying a statistically significant absolute call ‘present’ or
‘marginal’ in all samples.
qPCR and Analysis
The qPCRs were performed as described previously [42] with
some minor modifications. The primers were purchased from
Eurogentec (Seraing, Belgium). All primers had Tms between 59
and 61uC and all products were 100 to 150 bp long. GAPDH and
cyclophilin are used as internal standards to control amplification
variations due to differences in the starting mRNA concentration.
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